Daxor (FRA:DX5) Debt-to-Asset : 0.02 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Daxor Debt-to-Asset?

Daxor's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Daxor's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.69 Mil. Daxor's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was €31.98 Mil. Daxor's debt to asset for the quarter that ended in Dec. 2023 was 0.02.

Daxor Debt-to-Asset Historical Data

The historical data trend for Daxor's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daxor Debt-to-Asset Chart

Daxor Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.10

0.01

0.12

0.04

0.02

Daxor Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.12	0.13	0.04	-	0.02

Competitive Comparison of Daxor's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Daxor's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daxor's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Daxor's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Daxor's Debt-to-Asset falls into.

Daxor Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Daxor's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0.693)	/	31.975
	=	0.02

Daxor's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0.693)	/	31.975
	=	0.02

Daxor (FRA:DX5) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Daxor Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Daxor's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Daxor (FRA:DX5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (FRA:DX5) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

DXR:USA

Address

109 Meco Lane, Oak Ridge, TN, USA, 37830

Website

https://www.daxor.com

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

Daxor (FRA:DX5) Headlines

No Headlines